{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:17:01Z","timestamp":1790774221614,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006058","name":"St. Baldrick's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002618","name":"Aplastic Anemia and MDS International Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002618","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.exphem.2020.05.001","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T11:45:48Z","timestamp":1588938348000},"page":"21-27.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Cyclosporine enhances the sensitivity to lenalidomide in MDS\/AML in vitro"],"prefix":"10.1016","volume":"86","author":[{"given":"Xiaofei","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aixia","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saran","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Roman-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Lawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Wunderlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Mizukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Halene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amisha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2020.05.001_bib0001","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pharmthera.2012.07.004","article-title":"The application and biology of immunomodulatory drugs (IMiDs) in cancer","volume":"136","author":"Pan","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.exphem.2020.05.001_bib0002","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1182\/blood-2011-02-339721","article-title":"Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation","volume":"118","author":"Fang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.05.001_bib0003","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2005-11-4354","article-title":"Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461","volume":"108","author":"Farag","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.05.001_bib0004","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.exphem.2020.05.001_bib0005","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.exphem.2020.05.001_bib0006","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm.4127","article-title":"A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes","volume":"22","author":"Fang","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2020.05.001_bib0007","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nature04678","article-title":"NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21","volume":"441","author":"Arron","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2020.05.001_bib0008","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1152\/physrev.2000.80.4.1483","article-title":"Calcineurin: form and function","volume":"80","author":"Rusnak","year":"2000","journal-title":"Physiol Rev"},{"key":"10.1016\/j.exphem.2020.05.001_bib0009","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.4049\/jimmunol.165.7.3713","article-title":"Effects of a constitutively active form of calcineurin on T cell activation and thymic selection","volume":"165","author":"Hayden-Martinez","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2020.05.001_bib0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1358\/dnp.2003.16.5.829315","article-title":"Molecular actions of calcineurin inhibitors","volume":"16","author":"Hamawy","year":"2003","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.exphem.2020.05.001_bib0011","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1182\/blood-2014-02-556340","article-title":"OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues","volume":"123","author":"Wunderlich","year":"2014","journal-title":"Blood"},{"issue":"5 Pt 1","key":"10.1016\/j.exphem.2020.05.001_bib0012","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0190-9622(96)90726-4","article-title":"Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure","volume":"35","author":"Lowe","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.exphem.2020.05.001_bib0013","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1097\/01.ASN.0000034945.61533.26","article-title":"Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study","volume":"13","author":"Isnard Bagnis","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.exphem.2020.05.001_bib0014","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jaci.2009.01.065","article-title":"Low-dose cyclosporine is a good option for severe chronic urticaria","volume":"123","author":"Kessel","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.exphem.2020.05.001_bib0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies","volume":"2","author":"Kotla","year":"2009","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.exphem.2020.05.001_bib0016","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS","volume":"523","author":"Kronke","year":"2015","journal-title":"Nature"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X20301430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X20301430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:34:47Z","timestamp":1759566887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X20301430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":16,"alternative-id":["S0301472X20301430"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2020.05.001","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclosporine enhances the sensitivity to lenalidomide in MDS\/AML in vitro","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2020.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}